Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ARTEMIS-011
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
- NCT06935409 ↗
- Completed
- Hansoh BioMedical R&D Company
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Osteosarcoma
- Interventions
- HS-20093; Gemcitabine combined with docetaxel
- Arms
- HS-20093 · Experimental
- Gemcitabine combined with docetaxel · Active comparator
- Enrollment
- 122
- Primary outcomes
- PFS assessed by IRC as per RECIST 1.1 criteria
- Sponsor
- Hansoh BioMedical R&D Company
- Start
- Apr 25, 2025
- Primary completion
- Jun 17, 2026
- Results posted
- No
- Registry record
- NCT06935409 · updated Oct 19, 2026